|
CN108026159A
|
|
BTLA fusion protein activators and application thereof
|
|
AU2016255504A1
|
|
Novel EphA4 inhibitors targeting its ligand binding domain
|
|
US2018155426A1
|
|
Modulation of immune response using btla agonist antibodies
|
|
SG11201700095SA
|
|
Methods and compositions to modulate hair growth
|
|
EP3154954A1
|
|
Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
|
|
WO2015184011A2
|
|
Agonists of the apelin receptor and methods of use thereof
|
|
WO2015179436A1
|
|
Inflammation therapy using mekk3 inhibitors or blocking peptides
|
|
US2017036987A1
|
|
Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof
|
|
WO2015134790A1
|
|
Small molecule fatty acid synthase inhibitors
|
|
WO2015100267A1
|
|
Methods and compositions for treating cancer
|
|
WO2015081283A2
|
|
Long non-coding rna as a diagnostic and therapeutic agent
|
|
WO2015035063A2
|
|
MODULATION OF γδT CELLS
|
|
WO2014099999A1
|
|
Methods for improving cardiac contractility
|
|
CA2896577A1
|
|
Inhibitor of apoptosis protein (iap) antagonists
|
|
US2014005181A1
|
|
Small molecule antagonists of the apelin receptor for the treatment of disease
|
|
WO2013173642A1
|
|
High-throughput lipidomics
|
|
US2014134231A1
|
|
Mir-211 expression and related pathways in human melanoma
|
|
WO2013138665A1
|
|
Inhibitors of furin and other pro-protein convertases
|
|
US2015051138A1
|
|
Inhibitors of furin and other pro-protein convertases
|
|
WO2013126608A1
|
|
Sulfonamide compounds and uses as tnap inhibitors
|
